𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical and virological effects of long-term (over 5 years) lamivudine therapy

✍ Scribed by Yoshimasa Hashimoto; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Tetuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saito; Yoshiyuki Suzuki; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
100 KB
Volume
82
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Ideally, long‐term lamivudine therapy should not induce tyrosine–methionine–aspartate–aspartate (YMDD) mutants (reverse transcription [rt]; rt M204I/V) in patients with chronic hepatitis B. There is little or no information on the clinical features of patients who do not develop such mutants. We analyzed 368 patients who received lamivudine therapy for more than 6 months between 1995 and 2003. Among them, 98 patients were negative for YMDD mutants during 5‐year lamivudine therapy. Multivariate analysis identified hepatitis B e antigen (HBeAg) negativity, lack of cirrhosis, and high gamma glutamyltranspeptidase (GGTP) level as independent factors associated with lack of emergence of YMDD mutants during 5‐year treatment. In these 98 patients, 21 patients developed YMDD mutants in the 5‐year posttreatment follow‐up. Old age was identified as the only factor associated with the emergence of YMDD mutants during that period. For all patients, 53 showed no elevation of alanine aminotransferase (ALT) or viral load after emergence of YMDD mutants during 5 years. Short latency to emergence of YMDD mutants, mixed (tyrosine–isoleucine–aspartate–aspartate (YIDD) [rtM204I] + tyrosine–valine–aspartate–aspartate (YVDD) [rtM204V]) type, and low ALT level were identified as independent factors associated with elevation ALT or viral load. HBeAg negativity, lack of cirrhosis, and high GGTP level were associated with lack of emergence of YMDD mutants during 5‐year period. Young age protected against emergence of YMDD mutants over the 5‐year period. Moreover, after the emergence of YMDD mutants, short latency to the emergence of YMDD mutant, mixed type mutants, and low baseline ALT level were associated with elevation of ALT or viral load. J. Med. Virol. 82:684–691, 2010. © 2010 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Clinical course and predictive factors o
✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Long-term clinical and virological outco
✍ Natsuko Tsuda; Nobukazu Yuki; Kiyoshi Mochizuki; Takayuki Nagaoka; Masatoshi Yam 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB 👁 1 views

## Abstract Clinical relevance of occult hepatitis C virus (HCV) and/or hepatitis B virus (HBV) infection(s) remains uncertain years after interferon (IFN) therapy for chronic hepatitis C. By 1993, 38 sustained virological responders (SVRs) showing HCV RNA clearance at 6 months post‐treatment and 3

Clinical, virologic, histologic, and bio
✍ Sarah L. George; Bruce R. Bacon; Elizabeth M. Brunt; Kusal L. Mihindukulasuriya; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB

One hundred fifty patients with sustained virologic response (SVR) after treatment of chronic hepatitis C were enrolled in a long-term clinical follow-up study; patients were followed for 5 years for liver-related outcomes and evidence of biochemical or virologic relapse. Patients with stage 2 or gr

The effects of early selegiline therapy
✍ dr. med Jan P. Larsen; Jette Boas 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

## Abstract In this study, we investigated the effects of selegiline on levodopa treatment and parkinsonian disability over several years of treatment in patients with early Parkinson's disease (PD). The 163 patients were randomized to receive either selegiline or placebo in addition to levodopa in

Long-term monitoring shows hepatitis B v
✍ Daniel J. Tenney; Ronald E. Rose; Carl J. Baldick; Kevin A. Pokornowski; Betsy J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 742 KB

Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the